Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

5-Year checkup: does early labor induction affect child development?

NCT ID NCT07330336

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 4200 mothers and their children for 5 years to see if inducing labor at 39 weeks (instead of waiting for natural labor) affects the child's brain development. Researchers will assess thinking, language, movement, and behavior skills. The goal is to help pregnant women make informed choices about timing of labor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 4,200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Sep 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women randomized in the FRENCH-ARRIVE trial (NCT04799912): * Age ≥ 18 years * Nulliparous women (i.e. no previous pregnancy beyond 20 weeks) * With singleton gestation. Twin gestation reduced to singleton, either spontaneously or therapeutically, is not eligible unless the reduction occurred before 14 weeks project gestational age. * Gestational age at randomization between 37 weeks of gestation 0 day and 38 weeks of gestation 6 days inclusive based on the crown rump length measured at the first trimester ultrasound before 14 weeks of gestation and 0 days, as recommended in France * Affiliated or beneficiary to a health security system * Signed informed consent * Non-opposition from both holders of parental authority to participation in the FAMILY-FA study Exclusion Criteria: * Exclusion criteria of the FRENCH-ARRIVE trial: * Project gestational age at date of first ultrasound is \> 14 weeks * Plan for induction of labor prior to 40 weeks 5 days * Plan for cesarean delivery or contraindication to labor * Breech presentation * Multiple pregnancy * Signs of labor (regular painful contractions with cervical change) * Fetal demise or known major fetal anomaly * Heparin or low-molecular weight heparin during the current pregnancy * Placenta previa, accreta, vasa previa * Active vaginal bleeding greater than bloody show * Ruptured membranes * Cerclage in current pregnancy * Known oligohydramnios, defined as Amniotic Fluid Index \< 5 or Maximal Vertical Pocket \< 2 cm * Fetal growth restriction, defined as Estimated Fetal Weight \< 10th percentile according to local curve * Known HIV positivity because of modified delivery plan * Major maternal medical illness associated with increased risk for adverse pregnancy outcome (for example, any diabetes mellitus, lupus, any hypertensive disorder, cardiac disease, renal insufficiency) * Refusal of blood products * Participation in another interventional study that may influence management of labor or delivery (labor induction, operative vaginal delivery, cesarean section, shoulder dystocia) * Delivery planned elsewhere at a non-Network site * History of myomectomy by laparotomy or laparoscopy * Previous metroplasty for uterine malformation or Asherman syndrome * Patient under legal protection * Poor understanding of the French language * Moreover: the following postnatal criteria will be also exclusion criteria: * Major malformations and/or chromosomal aberrations evidenced in the child after birth * Parents' refusal to participate in the follow-up * Impossibility to contact the family

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neurodevelopmental disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Bordeaux

    Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.